World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 12 April 2021
Main ID:  EUCTR2014-000253-36-GR
Date of registration: 30/01/2017
Prospective Registration: Yes
Primary sponsor: MedImmune LLC
Public title: A Clinical Study to test the effect of the drug MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
Scientific title: A Double-masked, Placebo-controlled Study with Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders. - A Double-masked, Placebo-controlled Study with Open label Period to Evaluate MEDI-551 in NMO/NMOSD
Date of first enrolment: 31/03/2017
Target sample size: 212
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-000253-36
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: yes
Cross over: no
Other: yes
Other trial design description: Open label extension
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: no
Number of treatment arms in the trial: 2
 
Phase:  Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no
Countries of recruitment
Australia Bulgaria Canada Colombia Czech Republic Estonia Germany Greece
Hong Kong Hungary Israel Japan Korea, Republic of Mexico Moldova, Republic of Netherlands
New Zealand Peru Poland Portugal Russian Federation Serbia South Africa Spain
Taiwan Thailand Turkey Ukraine United States
Contacts
Name: Information Center   
Address:  One MedImmune Way MD 20878 Gaithersburg United States
Telephone: 13013980000
Email: informationcenter@astrazeneca.com
Affiliation:  MedImmune LLC
Name: Information Center   
Address:  One MedImmune Way MD 20878 Gaithersburg United States
Telephone: 13013980000
Email: informationcenter@astrazeneca.com
Affiliation:  MedImmune LLC
Key inclusion & exclusion criteria
Inclusion criteria:
1) Men and women 18 years or older with diagnosis of NMO/NMOSD.
2) Confirmation of NMO/NMOSD status:
a.) AQP4-IgG sero-positive NMO/NMOSD with at least one attack requiring rescue
therapy in the last year or two attacks requiring rescue therapy in the last 2 years.
b.) AQP4-IgG sero-negative NMO with at least one attack requiring rescue therapy in the
last year or two attacks requiring rescue therapy in the last 2 years.
3) Able and willing to give written informed consent and comply with the requirements of the study protocol.
4) EDSS <= 7.5 (8 in special circumstances).
5) Men and women of reproductive potential must agree to use a highly effective method of birth control from screening to 6 months after final dose of the investigational product.


Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 200
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 12

Exclusion criteria:
1) Lactating and pregnant females.
2) Treatment with any investigational agent within 4 weeks of screening.
3) Known history of a severe allergy or reaction to any component of the investigational product formulation or history of anaphylaxis following any biologic therapy.
4) Known active severe bacterial, viral, or other infection or any major episode of infection requiring hospitalization.
5) History of of alcohol, drug, or chemical abuse, or a recent history of such abuse < 1 year prior to randomization.
6) Receipt of the following at any time prior to randomization:
a) Alemtuzumab
b) Total lymphoid irradiation
c) Bone marrow transplant
d) T-cell vaccination therapy
7) Receipt of rituximab or any experimental B-cell depleting agent within 6 months prior screening and B-cells below the lower limit of normal.
8) Receipt of IVIG within 1 month prior to randomization.
9) Receipt of any of the following within 3 months prior to randomization:
a) Natalizumab (Tysabri®)
b) Cyclosporin
c) Methotrexate
d) Mitoxantrone
e) Cyclophosphamide
f) Tocilizumab
g) Eculizumab
10) History of Hepatitis B and/or Hepatitis C (Hep B/C at screening).
11) Known history of a primary immunodeficiency (congenital or acquired) or an underlying condition such as human immunodeficiency virus (HIV) infection.
12) History of malignancies, apart from squamous cell or basal cell carcinoma of the skin treated with documented success of curative therapy > 3 months prior to randomization.
13) Any concomitant disease other than NMO/NMOSD that required treatment with oral or intravenous steroids at doses over 20 mg a day for over 21 days.


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders (NMO/NMOSD)
MedDRA version: 19.1 Level: LLT Classification code 10029322 Term: Neuromyelitis optica System Organ Class: 100000004852
Intervention(s)

Product Name: MEDI-551
Product Code: MEDI-551
Pharmaceutical Form: Concentrate for solution for infusion
INN or Proposed INN: NA
CAS Number: 1299440-37-1
Current Sponsor code: MEDI-551
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Solution for infusion
Route of administration of the placebo: Intravenous use

Primary Outcome(s)
Primary end point(s): Time to an NMO/NMOSD attack determined by Adjudication Committee in randomized-control period
Timepoint(s) of evaluation of this end point: on or before Day 197
Main Objective: To compare the efficacy of MEDI-551 versus placebo in reducing the risk of an NMO/NMOSD attack
Secondary Objective: 1. To characterize the long-term efficacy of MEDI-551 by means of annualized attack rate.
2. To evaluate the safety and tolerability of MEDI-551
3. To characterize the pharmacokinetic (PK) profile and immunogenicity of MEDI-551
Secondary Outcome(s)
Secondary end point(s): 1. To characterize the long-term efficacy of MEDI-551 by means of annualized attack rate.
2. To evaluate the safety and tolerability of MEDI-551
3. To characterize the pharmacokinetic (PK) profile and immunogenicity of MEDI-551
Timepoint(s) of evaluation of this end point: End of Randomized-controlled Period and End of Study
Secondary ID(s)
NCT02200770
2014-000253-36-CZ
CD-IA-MEDI-551-1155
Source(s) of Monetary Support
MedImmune LLC
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date: 31/03/2017
Contact:
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey